Nirmatrelvir-Ritonavir Reduces Long COVID Risk in Older Adults, Not Adolescents
Nirmatrelvir-ritonavir reduced the risk for long COVID in adults aged 50 years and older but not in adolescents.
Treatment of acute COVID-19 with nirmatrelvir-ritonavir is associated with a lower risk of developing long COVID in adults aged 50 years and older, but not in adolescents, according to study results published in Open Forum Infectious Diseases.
Long COVID encompasses more than 200 symptoms ranging from fatigue and shortness of breath to cardiovascular disease and diabetes.
While the antiviral nirmatrelvir-ritonavir is well-established in reducing hospitalization and death in acute COVID-19, its potential to mitigate long-term sequelae remains uncertain.
Researchers conducted a retrospective cohort study using United States HealthVerity claims data to evaluate whether treatment with nirmatrelvir-ritonavir during acute illness reduces long COVID risk across different age groups (12-17, 18-49, 50-64, and ≥65 years).
No direct quote available in the text.
Author's summary: Nirmatrelvir-ritonavir reduces long COVID risk in older adults.
More News
- Israel Tried to Destroy Gazans' Peoplehood; It Failed | Common Dreams
- U.S. Intelligence Is Being Blinded by Trumpian Politics
- Ciryl Gane breaks silence after eye pokes stopped Tom Aspinall fight
- Blue Jays infielder Bo Bichette not in starting lineup for Game 2 of World Series against Dodgers - The Boston Globe
- Letter to the Editor: Reinstate Tom Hayes
- Op-Ed: Identity Is the cybersecurity perimeter in maritime operations
- Kamala Harris To Run For US President Again
- The Unvanquished Will: Gaza’s Triumph Of Spirit Against The Architecture Of Genocide
- Alabama high school football final scores from Tuscaloosa area in Week 9